Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 5/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25919620 | 0.71 | F11 (0.35) | USP30LPLLIPG | |
| SCHEMBL2147093 | 0.70 | DGAT1 (0.45) | LPLLIPGIRAK4 | |
| SCHEMBL12715453 | 0.69 | USP30 (0.43) | USP30LPLLIPGP2RX7FFAR1 | |
| SCHEMBL2220822 | 0.68 | LIPG (0.42) | LPLLIPGIRAK4 | |
| SCHEMBL4674549 | 0.67 | LPL (0.38) | NOS1LPLLIPGP2RX7MAPK1 | |
| SCHEMBL31630516 | 0.67 | NOS1 (0.35) | NOS1 | |
| SCHEMBL1284338 | 0.65 | LPL (0.42) | LPLLIPGFFAR1IRAK4 | |
| SCHEMBL2379522 | 0.65 | USP30 (0.43) | USP30LPLLIPGP2RX7FFAR1 | |
| SCHEMBL2679491 | 0.65 | SNCA (0.39) | LPLLIPGFFAR1IRAK4 | |
| SCHEMBL5062546 | 0.64 | LPL (0.41) | LPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| CN-115298176-A | Compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | NOS1 847/4885USP30 4320/4885LPL 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.